Sildenafil and retinopathy of prematurity risk in very low birth weight infants by Samiee-Zafarghandy, et al.
Sildenafil and Retinopathy of Prematurity Risk in Very Low Birth 
Weight Infants
Samira Samiee-Zafarghandy, MDa,b,c, John N. van den Anker, MD, PhDa,b,d,e, Matthew M. 
Laughon, MD, MPHf, Reese H. Clark, MDg, P. Brian Smith, MD, MPH, MHSh,i, and Christoph 
P. Hornik, MD, MPHh,i on behalf of the Best Pharmaceuticals for Children Act – Pediatric 
Trials Network Administrative Core Committee*
aCenter for Translational Science, Children’s National Medical Center, Washington, DC, USA 
bDivision of Clinical Pharmacology, Children’s National Medical Center, Washington, DC, USA 
cDepartment of Pediatrics, McMaster University Medical Center, Hamilton, Ontario, Canada 
dIntensive Care, Erasmus Medical Center-Sophia Children’s Hospital, Rotterdam, the Netherlands 
eDepartment of Paediatric Pharmacology, University Children’s Hospital Basel, Switzerland 
fDepartment of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, USA 
gPediatrix-Obstetrix Center for Research and Education, Sunrise, FL, USA hDuke Clinical 
Research Institute, Duke University School of Medicine, Durham, NC, USA iDepartment of 
Pediatrics, Duke University School of Medicine, Durham, NC, USA
Abstract
Objective—To examine the effect of sildenafil therapy on development of severe retinopathy of 
prematurity (ROP) requiring surgical intervention in premature infants.
Study Design—We identified premature infants who were discharged from Pediatrix Medical 
Group neonatal intensive care units from 2003–2012 and who received an ophthalmologic exam. 
We matched each infant exposed to sildenafil prior to first eye exam to three non-exposed infants 
using propensity scoring to control for differences in baseline infant characteristics. We evaluated 
the association between sildenafil exposure and development of severe ROP using conditional 
logistic regression.
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Result—Of the 57815 infants meeting inclusion criteria, 88 were exposed to sildenafil. We 
matched 81/88 (92%) sildenafil-exposed with 243 non-exposed infants. There was no difference in 
the proportion of infants who developed severe ROP in the sildenafil-exposed vs. non-exposed 
groups (17/81 [21%] vs. 38/243 [16%], P=0.27). On adjusted analysis, there was no difference in 
severe ROP in the sildenafil-exposed versus non-exposed infants (odds ratio=1.46, 95% 
confidence interval=0.76–2.82, P=0.26).
Conclusion—We did not observe an association between risk of severe ROP and sildenafil 
exposure prior to first eye exam in this cohort of premature infants.
INTRODUCTION
Sildenafil is increasingly used off-label for treatment of pulmonary hypertension (PH) of 
various etiologies in infants and children.1 Persistent pulmonary hypertension of the 
newborn (PPHN) and PH associated with congenital heart disease, chronic lung disease, or 
congenital diaphragmatic hernia are common conditions treated with sildenafil therapy in 
term and preterm infants.2
The therapeutic effect of sildenafil in PH occurs through its inhibitory action on 
phosphodiesterase type 5 (PDE5), which results in nitric oxide (NO)-mediated 
vasorelaxation.3 Despite the high selectivity of sildenafil for PDE5 enzymes, it also inhibits 
the retina-specific phosphodiesterase type 6 (PDE6) with one-tenth the potency compared 
with PDE5.3 Expression of PDE6 enzymes in rod and cone photoreceptors of retinal tissue, 
as well as the discovery of PDE5 enzymes on retinal and choroid vasculature, have raised 
concerns about potential adverse effects of sildenafil on the developing eye of premature 
infants.3–5
Because of the increasing use of sildenafil despite the lack of population-specific safety 
data,6 we sought to examine the association between sildenafil therapy and the development 
of severe retinopathy of prematurity (ROP), requiring therapy in hospitalized, very low birth 
weight (VLBW) infants (≤1500 g).
METHODS
Data Source
Data were obtained from the Pediatrix Medical Group Data Warehouse, which prospectively 
captures information from an electronic medical record of daily progress notes and other 
documentation of clinicians involved in the care of infants (https://www.pediatrix.com/
PediatrixUniversity). We included all inborn infants ≤32 weeks gestational age (GA) and 
≤1500 g birth weight (BW) who received an ophthalmologic exam and were discharged 
from one of the 326 North American neonatal intensive care units (NICUs) managed by the 
Pediatrix Medical Group from 2003–2012. Infants who started sildenafil therapy after their 
initial ROP examination or after 36 weeks postmenstrual age were excluded. Information 
regarding maternal history, infant demographics, respiratory and hemodynamic support, 
medications, culture results, and ophthalmologic exams were obtained.
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Definitions
The primary outcome of our study was severe ROP, defined as any ROP requiring surgical 
intervention, cryotherapy, laser therapy, or treatment with bevacizumab. We defined 
sildenafil exposure as any sildenafil therapy prior to the initial ophthalmologic examination, 
and calculated cumulative exposure to sildenafil as the number of days of exposure to 
sildenafil prior to the initial ophthalmologic examination. We defined history of bacteremia 
as a binary variable: if the infant had at least one positive blood culture with organisms not 
considered a contaminant prior to or on the infant day of hospitalization. We defined 
cumulative daily inotropic support, mechanical ventilation, and supplemental oxygen as the 
cumulative days of exposure to any inotropic drug (dobutamine, dopamine, epinephrine, 
milrinone/amrinone, norepinephrine), any mechanical ventilation, and any fraction of 
inspired oxygen (FiO2) >21% up until each infant day of hospitalization. We defined small 
for gestational age (SGA) as previously described.7
Statistical Analysis
We used medians with interquartile ranges and counts with percentages to describe 
continuous and categorical variables, respectively. We compared the distribution between 
infants with and without sildenafil exposure using Wilcoxon rank sum, chi-square, and 
Fisher’s exact tests where appropriate. Because more severely ill infants are more likely to 
receive sildenafil therapy and are at higher risk of developing ROP, we used propensity 
scores to match infants in a 3:1 ratio (non-exposed:exposed) to ensure comparison of similar 
infants.8 A propensity score for sildenafil exposure or non-exposure on each infant day of 
hospitalization was estimated using multivariable logistic regression including covariates 
that might predict both sildenafil therapy and ROP risk: GA in weeks, postnatal age (PNA) 
in days, sex, race/ethnicity, Apgar score at 5 minutes, SGA status, antenatal steroid 
exposure, bacteremia, mechanical ventilation, inotropic support, and supplemental oxygen, 
as defined above.9 We matched infants on the first day of sildenafil exposure with three non-
exposed infants using nearest-neighbor matching without replacement. Matching was 
allowed only if the difference in propensity score between case and control was <0.01. We 
assessed covariate balance across treatment groups by comparing covariate means, 
histograms, and Kernel density plots of propensity scores across the two groups. We used 
Stata’s psmatch2 routine that implements full Malhanobis and a variety of propensity score 
matching methods.10 We compared the distribution of covariates between the two groups 
after propensity matching using Wilcoxon rank sum, chi-square, or Fisher’s exact tests 
where appropriate. We used conditional (fixed effects) logistic regression to evaluate the 
association between any sildenafil exposure prior to ROP evaluation and risk of severe ROP 
conditioned on the matched pair. In an a priori defined secondary analysis, we used 
conditional logistic regression to evaluate the association between risk of severe ROP and 
cumulative duration of sildenafil exposure as defined above, and categorized as 0 days, 1–7 
days, 8–14 days, and >14 days. The study was approved by the Duke University Institutional 
Review Board without the need for written informed consent as the datasets used did not 
contain any patient identifiers.
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RESULTS
We identified 57815 VLBW infants meeting inclusion criteria, of whom 88 (0.2%) were 
exposed to sildenafil (Figure 1). The median (25th, 75th percentile) BW and GA of the entire 
cohort were 1006 g (830, 1270) and 28 weeks (26, 30), respectively. Median GA and BW 
were lower in infants exposed to sildenafil compared with those not exposed (GA 25 weeks 
[24, 27] vs. 28 weeks [26, 30], P<0.001 and BW 665 g [535, 813] vs. 1006 g [833, 1270], 
P<0.001). Infants exposed to sildenafil were also more likely to be SGA, had lower 5-minute 
Apgar scores, and more exposure to inotropic drugs, ventilator support, and supplemental 
oxygen compared with those not exposed to sildenafil (Table 1). The proportion of infants 
who developed severe ROP was higher in the sildenafil-exposed compared with the non-
exposed group—18/88 (21%) vs. 2546/57727 (4%), P<0.001.
We successfully matched 81/88 (92%) sildenafil-exposed with 243/57 727 (<1%) non-
exposed infants. Following matching, characteristics between groups were well balanced, 
and there were no statistically significant differences between the sildenafil-exposed and 
non-exposed infants in baseline demographics, cumulative days of inotropic exposure, 
mechanical ventilation, or oxygen therapy. Median PNA at the time of severe ROP therapy 
also did not differ significantly between sildenafil-exposed and non-exposed infants (93 days 
[74, 99] vs. 87 days [73, 102], P=0.95), nor did median PMA (37 weeks [36, 38] vs. 37 
weeks [35, 39], P=0.86).
After matching, the proportion of infants who developed severe ROP was similar in the 
sildenafil-exposed vs. non-exposed infants (17/81 [21%] vs. 38/243 [16%], P=0.27). There 
was no significant difference in the odds of severe ROP in the sildenafil-exposed versus non-
exposed infants (odds ratio=1.46, 95% confidence interval=0.76–2.82, P=0.26). The median 
duration of sildenafil therapy was 10 days (2, 31). Duration of sildenafil therapy was 1–7 
days in 35/81 infants (43%), 8–14 days in 10/81 infants (12%), and >14 days in 36/81 
infants (44%). Increasing duration of sildenafil exposure prior to initial eye exam was also 
not associated with increased risk for development of severe ROP compared with the non-
exposed infants (Table 2).
DISCUSSION
We present the results of a propensity score-matched, case-control study of hospitalized 
VLBW infants exposed to sildenafil prior to their first ROP evaluation. Following matching, 
groups were well balanced for available risk factors of ROP, and we observed no difference 
in the risk of severe ROP in infants exposed to sildenafil. This observation remained when 
using duration of sildenafil exposure as a predictor of severe ROP.
Reported potential ocular adverse effects of sildenafil in infants are limited. A case report 
described a 26-week premature infant who developed aggressive ROP while receiving 
sildenafil therapy.5 The infant had a complicated clinical course, including three episodes of 
bacterial and fungal sepsis, and required 100% oxygen therapy for up to 32 weeks corrected 
GA. In a retrospective, single-center, case-control study, 17 infants <30 weeks gestation 
exposed to sildenafil were compared with 51 control infants for progression of ROP or need 
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for laser treatment.11 Sildenafil was started at median of 36 weeks corrected GA and 
continued for a median duration of 52 days. The treated and untreated groups were not 
similar in their baseline characteristics, with infants in the sildenafil group requiring more 
respiratory support. The time of ROP assessment relative to the timing of sildenafil therapy 
was unclear. This study did not observe any effect of sildenafil on ROP progression or need 
for laser treatment. Another retrospective, single-center study assessed 22 term and later 
preterm infants not at risk for ROP or for development of any other ocular complications 
following 2–36 weeks of treatment with sildenafil.12 All infants received an ophthalmologic 
assessment at chronological age of 2–40 weeks indicated specifically due to sildenafil 
therapy. This study did not find any ocular complications related to the use of sildenafil.
We report the first multicenter study evaluating the association between early sildenafil 
exposure and severe ROP. In addition to larger sample size, we were able to control for 
several known ROP risk factors in our analysis through propensity score matching. This 
matching was essential given the significant differences in ROP risk factors between the 
unmatched populations. Our results are in agreement with the existing limited evidence that 
sildenafil therapy does not increase the risk for development of severe ROP in premature 
infants.
Sildenafil is a predominant PDE5 inhibitor with vasodilatory properties in widespread use 
since its initial approval in adults.13 The promising results of sildenafil for treatment of PH 
in adults have resulted in its increasing use in infants.1,2 In a recent review of medication use 
in hospitalized infants, sildenafil had the second highest relative increase in use, up by over 
11-fold, from 0.2 to 2.3 per 1000 infants from 2005–2010.6 Reports of visual disturbances in 
adults treated for erectile dysfunction, although mostly mild and transient, drew considerable 
attention to the potential adverse effects of sildenafil on the ocular system.14–18 These 
effects have been attributed to its cross-inhibition of the retinal photoreceptor-specific PDE6 
enzyme, as well as the recent discovery of PDE5 enzymes in the retinal and choroidal 
vasculature.19 Alterations of the NO signaling pathway, increase in intraocular pressure, 
changes in choroidal blood flow or thickness, and variation of retinal perfusion have been 
raised as potential mechanisms for the observed adverse effect of sildenafil on the ocular 
system.20–22 NO is an important determinant of choroidal and retinal blood flow in the 
developing eye of premature infants. It is known to have inhibitive effect on retinal vascular 
obliteration and subsequently proliferative retinopathies, but it can also increase 
neoangiogenic activity via vascular endothelial growth factor (VEGF)-induced 
angiogenesis.23 It is not known whether any of these sildenafil induced changes in NO 
signaling pathways affects the development and progression of ROP.
Our study is limited in its retrospective nature and data obtained from electronic 
documentation of clinical care rather than from a prospectively established research 
database. Most importantly, at the time of this analysis, sildenafil dosing and indication were 
not completely captured in the database, and we were unable to examine any potential 
associations between sildenafil dosing, exposure, and ROP risk. This limitation is 
particularly relevant as the ocular safety of sildenafil may be dose-dependent. Dose 
dependency has been suggested in rat models of PDE-6 expression, which is increasingly 
down regulated with higher doses of sildenafil.24,25 Moreover, details from the ocular 
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examination, including exact timing of diagnosis or early findings suggestive of increased 
ROP risk and severity and extent of ROP, were not available, and we were unable to stratify 
infants according to the International Classification of Retinopathy of Prematurity system.26 
Instead, we had to use ROP intervention during hospitalization as a surrogate for severity, 
and the decision to treat ROP was at the discretion of the local provider. Outpatient follow 
up data to identify later diagnoses of ROP or resulting blindness were also not available. We 
examined infants with early sildenafil exposure and used propensity score matching, 
resulting in balanced groups with regard to baseline risk of ROP.27 Our results add to the 
safety profile of sildenafil as an off-label medication in infants and show that infants who 
were exposed to sildenafil at a very young age did not have a higher risk for development of 
severe ROP.
CONCLUSION
We did not observe an increased risk of ROP in premature infants treated with sildenafil 
prior to their first ROP exam. These results support the conduct of future prospective trials 
characterizing the safety and efficacy of sildenafil in premature infants.
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Figure 1. 
Study flow diagram. Abbreviations: BW, birth weight; GA, gestational age; NICU, neonatal 
intensive care unit; ROP, retinopathy of prematurity.
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Table 2
Frequency and adjusted odds ratio of severe ROP in matched infants
ROP n (%) Adjusted Odds Ratio (95% Confidence Interval)
Sildenafil exposure status
 Non-exposed 38/243 (16%) REFERENCE
 Exposed 17/81 (21%) 1.46 (0.76–2.82)
Days of exposure to sildenafil
 0 38/243 (16%) REFERENCE
 ≤7 6/35 (17%) 0.83 (0.30–2.26)
 7–14 3/10 (30%) 5.61 (0.55–57.3)
 >14 8/36 (22%) 2.04 (0.73–5.69)
Abbreviation: ROP, retinopathy of prematurity.
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